Albendazole 400 mg (Micronised), 10 Tablets (1 Strip) — TM Albentel

ALBENTEL (Micronised Albendazole)

ALBENTEL contains micronised Albendazole (400 mg per tablet), manufactured by Winlife Lifesciences Pvt. Ltd. under United States Pharmacopeia (USP) standards. In oncology research and off-label therapeutic evaluation, micronised Albendazole is recognised as a potent microtubule-destabilising agent, a metabolic disruptor and an angiogenesis inhibitor. This listing covers a single blister strip of 10 tablets — a compact, standardised quantity for pilot and short-cycle research protocols.

General Pharmaceutical & Manufacturer Information

• Brand Name: ALBENTEL (Micronised Albendazole)
• Active Ingredient: Albendazole USP (micronised form, for enhanced bioavailability)
• Dosage: 400 mg of Albendazole per uncoated chewable tablet
• Form: Oral chewable tablets
• Package Size: 1 Strip (10 tablets)
• Manufacturer: Winlife Lifesciences Pvt. Ltd.
• CAS Number: 54965-24-1
• Molecular Formula: C12H15N3O2S

Therapeutic & Off-Label Mechanisms in Oncology Research

In drug-repurposing and translational cancer research, Albendazole exhibits preclinical activity across diverse tumour cell lines through several distinct bio-molecular mechanisms:

• Microtubule Polymerisation Inhibition: High-affinity binding to the colchicine-binding site of β-tubulin prevents tubulin polymerisation, causing spindle apparatus breakdown, G2/M phase cell-cycle arrest and subsequent mitotic catastrophe.
• Anti-Angiogenic Pathway Suppression: Inhibits vascular endothelial growth factor (VEGF) expression and downregulates hypoxia-inducible factor 1-alpha (HIF-1α), preventing tumour microvascularisation and nutrient recruitment.
• Glycolytic Suppression & Glucose Transport Inhibition: Inhibits glucose uptake in malignant cells by targeting GLUT-family transporters, leading to ATP depletion, metabolic collapse and mitochondria-mediated apoptosis.
• Induction of Apoptosis & p53 Modulation: Promotes cytochrome c release from mitochondria, activating downstream caspase-3 and caspase-9 cascades while upregulating p53 tumour-suppressor activity.
• Inhibition of Cancer Cell Migration & Invasion: Downregulates matrix metalloproteinases (MMP-2 and MMP-9), inhibiting extracellular matrix breakdown and reducing invasive and metastatic capacity in aggressive tumour phenotypes.

Scientific Context & References

1. Microtubule & Apoptosis Mechanisms: Studies published in Cancer Research and Biochimica et Biophysica Acta (BBA) demonstrate Albendazole’s ability to bind β-tubulin, halt cell-cycle progression at G2/M and trigger mitochondrial apoptosis in carcinoma lines.
2. Anti-Angiogenesis & VEGF Suppression: Research in Molecular Cancer Therapeutics confirms that Albendazole suppresses VEGF-driven endothelial cell proliferation and tube formation in preclinical models.
3. Micronisation & Bioavailability: Peer-reviewed literature in the European Journal of Pharmaceutics and Biopharmaceutics notes that micronised formulations significantly improve dissolution rates and cellular accumulation compared with standard crude active pharmaceutical ingredients (APIs).

Storage & Handling

• Store in a cool, dark and dry place.
• Protect from direct light and moisture.
• Keep out of reach of children.

Strict Regulatory Disclaimer: This product is intended solely for laboratory research, in vitro evaluation, and analytical purposes. We do not provide medical advice, recommend specific protocols, or guarantee any therapeutic results. Nothing stated herein should be construed as a medical recommendation or a guarantee of efficacy in treating, curing, or preventing any disease, including cancer. Any practical application of this compound must be strictly validated by independent research and overseen by a qualified professional.